BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. Am Heart J 2018;201:141-8. [PMID: 29803986 DOI: 10.1016/j.ahj.2018.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Yamada S, Jeon R, Garmany A, Behfar A, Terzic A. Screening for regenerative therapy responders in heart failure. Biomark Med 2021;15:775-83. [PMID: 34169733 DOI: 10.2217/bmm-2020-0683] [Reference Citation Analysis]
2 Raval AN, Johnston PV, Duckers HJ, Cook TD, Traverse JH, Altman PA, Dhingra R, Hematti P, Borrello I, Anderson RD, Pepine CJ. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. Int J Cardiol 2021;326:131-8. [PMID: 33091520 DOI: 10.1016/j.ijcard.2020.10.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Johnston PV, Duckers HJ, Raval AN, Cook TD, Pepine CJ. Not All Stem Cells Are Created Equal: The Case for Prospective Assessment of Stem Cell Potency in the CardiAMP Heart Failure Trial. Circ Res 2018;123:944-6. [DOI: 10.1161/circresaha.118.313425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cassani M, Fernandes S, Vrbsky J, Ergir E, Cavalieri F, Forte G. Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. Front Bioeng Biotechnol 2020;8:323. [PMID: 32391340 DOI: 10.3389/fbioe.2020.00323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Bolli R, Solankhi M, Tang XL, Kahlon A. Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts. Cardiovasc Res 2021:cvab135. [PMID: 33871588 DOI: 10.1093/cvr/cvab135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tajabadi M, Goran Orimi H, Ramzgouyan MR, Nemati A, Deravi N, Beheshtizadeh N, Azami M. Regenerative strategies for the consequences of myocardial infarction: Chronological indication and upcoming visions. Biomed Pharmacother 2021;146:112584. [PMID: 34968921 DOI: 10.1016/j.biopha.2021.112584] [Reference Citation Analysis]
7 Vaka R, Davis DR. State-of-play for cellular therapies in cardiac repair and regeneration. Stem Cells 2021. [PMID: 34448513 DOI: 10.1002/stem.3446] [Reference Citation Analysis]
8 Raval AN, Pepine CJ. Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting. Cardiovasc Revasc Med 2021;22:100-8. [PMID: 32651159 DOI: 10.1016/j.carrev.2020.06.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Raval AN. Clinical Trial Design for Investigational Cardio-Regenerative Therapy. Adv Exp Med Biol 2018;1098:199-211. [PMID: 30238373 DOI: 10.1007/978-3-319-97421-7_11] [Reference Citation Analysis]
10 Nakamura K, Murry CE. Function Follows Form - A Review of Cardiac Cell Therapy. Circ J. 2019;83:2399-2412. [PMID: 31723070 DOI: 10.1253/circj.cj-19-0567] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]